Articles related to CHEMOTHERAPY

“Patients treated in the Optune Pax arm had a median time to pain progression of 15.2 months compared to 9.1 months.” — PANOVA-3 Trial, FDA Approval Announcement

“The damage to DNA lasts a lifetime. Probably the biggest concern is the increased risk of other cancers developing as a result of exposure to prior chemotherapy.”

Final analysis confirms venetoclax plus modified intensive chemotherapy achieves durable remissions with 17.9-month treatment-free intervals in fit elderly AML patients, particularly those with de novo disease.

Experts note that the use of chemotherapy can indicate cancer spread beyond its origin, potentially reflecting the stage, aggressiveness, or progression potential of the disease.

Recent research from Brown University suggests that the SARS-CoV-2 spike protein could interfere with cancer treatment efficacy by affecting the p53 gene’s ability to suppress tumor growth and repair DNA.

Explore new horizons in advanced hepatocellular carcinoma treatment with emerging data on lenvatinib and cisplatin’s potential efficacy as a second-line therapy and the promising triple combination therapy showing significant response rates.